Jefferies Group

SiriusPoint Announces Pricing of Tender Offer for 4.600% Senior Notes due 2026

Retrieved on: 
Thursday, April 4, 2024
Tax, COVID-19, Acquisition, Security (finance), Insurance, Tender offer, Note, Expiration, Investment, Annual report, BMO Capital Markets, HSBC, Jefferies Group, Solicitation, Amendment, J.P. Morgan & Co.

Those who validly tender 2026 Notes and deliver consents before the Early Expiration Time will receive the Total Consideration for each $1,000 principal amount of accepted 2026 Notes.

Key Points: 
  • Those who validly tender 2026 Notes and deliver consents before the Early Expiration Time will receive the Total Consideration for each $1,000 principal amount of accepted 2026 Notes.
  • Those who validly tender 2026 Notes and deliver consents after the Early Expiration Time will receive the Total Consideration, less $50, for each $1,000 principal amount of accepted 2026 Notes.
  • The Tender Offer expires at 5:00 p.m., New York City time, on April 19, 2024, unless extended or earlier terminated by SiriusPoint (the “Tender Offer Expiration”).
  • SiriusPoint has further reserved the right, in its sole discretion, not to accept any tenders of 2026 Notes or deliveries of consents with respect to the 2026 Notes.

Genco Shipping & Trading Limited Files Preliminary Proxy Statement

Retrieved on: 
Wednesday, April 3, 2024
Annual general meeting, GNK, LLP, Transport, Security (finance), Jefferies Group

In regards to the Board’s recommendation, Genco issued the following statement:

Key Points: 
  • In regards to the Board’s recommendation, Genco issued the following statement:
    The Genco Board and management team are committed to maintaining strong corporate governance while creating long-term value for all shareholders.
  • Genco’s preliminary proxy materials can be found here as well as on the Company’s website at https://www.gencoshipping.com/.
  • The Genco Board recommends that shareholders discard any proxy materials from GK Investor and vote using the WHITE proxy card they will receive as part of the definitive proxy materials that will be delivered by the Company.
  • Jefferies LLC is acting as financial advisor to Genco, and Kramer Levin Naftalis & Frankel LLP is serving as legal counsel.

Asensus Surgical, Inc. Announces Non-Binding Acquisition Proposal and Exclusivity Arrangement with KARL STORZ SE & Co. KG

Retrieved on: 
Wednesday, April 3, 2024
Letter, Comment, Bridge loan, Sale, Promissory note, Jefferies Group, KARL

KARL STORZ has communicated that the proposed purchase price represents its “best and final” offer to the Company.

Key Points: 
  • KARL STORZ has communicated that the proposed purchase price represents its “best and final” offer to the Company.
  • During the exclusivity period, KARL STORZ will be conducting diligence and the parties will be negotiating a definitive merger agreement.
  • In conjunction with the letter of intent, Asensus has entered into a fully secured Promissory Note (the “Bridge Loan”) with KARL STORZ.
  • Asensus and KARL STORZ plan to work diligently during the exclusivity period to negotiate and finalize a definitive merger agreement.

Marex Group plc Announces Filing of Registration Statement for Proposed Initial Public Offering

Retrieved on: 
Tuesday, March 26, 2024
Attention, Seventh Avenue, Madison Avenue, Goldman Sachs, 4th floor, Form, Keefe, Bruyette & Woods, Marex, Sale, Prospectus, Broadridge Financial Solutions, Jefferies, Equity capital markets, Jefferies Group, Barclays, Cryptocurrency

NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Marex Group (“Marex”), the diversified global financial services platform, today announces that it has publicly filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares.

Key Points: 
  • NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Marex Group (“Marex”), the diversified global financial services platform, today announces that it has publicly filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares.
  • The timing of the offering, number of shares to be offered and the price range for the proposed offering have not yet been determined.
  • Barclays, Goldman Sachs & Co. LLC, Jefferies, and Keefe, Bruyette & Woods, a Stifel Company, are acting as joint lead book-running managers for the proposed offering.
  • A registration statement relating to these securities has been filed with the SEC but has not yet become effective.

Model N to be Acquired by Vista Equity Partners For $1.25 Billion

Retrieved on: 
Monday, April 8, 2024
Professional Services, Health, Data Analytics, Technology, Health Technology, Other Technology, Pharmaceutical, Culture, Growth, ARR, Model N, Sale, LLP, Senior, Medtech, Vista Equity Partners, Model, Jefferies Group, Kirkland & Ellis, HSR

Model N (NYSE: MODN), a leader in revenue optimization and compliance for pharmaceutical, medtech, and high-tech innovators, today announced that it has entered into a definitive agreement to be acquired by Vista Equity Partners (“Vista”), a leading global investment firm focused exclusively on enterprise software, data, and technology-enabled businesses.

Key Points: 
  • Model N (NYSE: MODN), a leader in revenue optimization and compliance for pharmaceutical, medtech, and high-tech innovators, today announced that it has entered into a definitive agreement to be acquired by Vista Equity Partners (“Vista”), a leading global investment firm focused exclusively on enterprise software, data, and technology-enabled businesses.
  • Under the terms of the agreement, Vista will acquire all the outstanding shares of Model N common stock for $30.00 per share in an all-cash transaction valued at approximately $1.25 billion.
  • Upon completion of the transaction, Model N will become a privately held company and shares of Model N common stock will no longer be listed on any public market.
  • Jefferies LLC is serving as exclusive financial advisor and provided a fairness opinion to Model N, and Fenwick & West LLP is serving as legal counsel.

SiriusPoint Announces Notes Offering, Tender Offer for 4.600% Senior Notes due 2026 and Redemption of 7.00% Senior Notes due 2025

Retrieved on: 
Thursday, March 21, 2024
Tax, Debt, Sale, Tender offer, Investment, BMO Capital Markets, HSBC, Treasury, Bank, Consent, Tender, BNY Mellon, Solicitation, Acquisition, Security (finance), Insurance, Annual report, COVID-19, CUSIP, Expiration, Jefferies Group, J.P. Morgan & Co.

Those who validly tender 2026 Notes and deliver consents before the Early Expiration Time will receive the Total Consideration for each $1,000 principal amount of accepted 2026 Notes.

Key Points: 
  • Those who validly tender 2026 Notes and deliver consents before the Early Expiration Time will receive the Total Consideration for each $1,000 principal amount of accepted 2026 Notes.
  • Those who validly tender 2026 Notes and deliver consents after the Early Expiration Time will receive the Total Consideration, less $50, for each $1,000 principal amount of accepted 2026 Notes.
  • The Tender Offer will expire at 5:00 p.m., New York City time, on April 19, 2024, unless extended or earlier terminated by SiriusPoint (the “Tender Offer Expiration”).
  • No recommendation is made as to whether holders should tender their 2026 Notes or deliver their consents with respect to the 2026 Notes.

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Retrieved on: 
Tuesday, March 19, 2024
SVB Securities, BofA Securities, Madison Avenue, Form, Telephone, Patient, SAN, Sale, Attention, Cancer, Security (finance), Therapy, OrbiMed, Jefferies, IPSC, State Street, Jefferies Group

The offering includes participation from new and existing institutional investors, including Adage Capital Partners LP., Boxer Capital, Deep Track Capital, OrbiMed, Suvretta Capital and a life-sciences focused investor.

Key Points: 
  • The offering includes participation from new and existing institutional investors, including Adage Capital Partners LP., Boxer Capital, Deep Track Capital, OrbiMed, Suvretta Capital and a life-sciences focused investor.
  • The gross proceeds from the underwritten offering and private placement are expected to be approximately $100.0 million before deducting underwriting discounts and commissions and other offering expenses.
  • BofA Securities, Jefferies, and Leerink Partners are acting as the joint bookrunning managers for the underwritten offering.
  • A final prospectus supplement relating to and describing the terms of the underwritten offering will be filed with the SEC and will be available on the SEC’s web site at www.sec.gov.

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

Retrieved on: 
Tuesday, March 19, 2024
Montgomery Street, Fatty liver disease, UBS, ECM, Madison Avenue, Goldman Sachs, Form, Telephone, Citizenship, Research, Sale, Public expenditure, Attention, Security (finance), Lexington Avenue, Prospectus, Suite, Jefferies, NASH, Therapy, Nicollet Mall, Equity capital markets, Jefferies Group, ATTN:, Evercore

The size of the offering was increased by $100 million subsequent to the initial announcement of the offering.

Key Points: 
  • The size of the offering was increased by $100 million subsequent to the initial announcement of the offering.
  • The gross proceeds to Madrigal from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $600 million.
  • Madrigal has granted the underwriters of the offering a 30-day option to purchase up to an additional 346,153 shares of common stock from the company at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about March 21, 2024, subject to the satisfaction of customary closing conditions.

Madrigal Pharmaceuticals Announces Proposed Public Offering

Retrieved on: 
Monday, March 18, 2024
Montgomery Street, Fatty liver disease, UBS, ECM, Madison Avenue, Goldman Sachs, Form, Telephone, Citizenship, Research, Sale, Public expenditure, Attention, Security (finance), Lexington Avenue, Prospectus, Suite, Jefferies, NASH, Therapy, Nicollet Mall, Equity capital markets, Jefferies Group, ATTN:, Evercore

Madrigal also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • Madrigal also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions.
  • All of the shares in the proposed offering are to be sold by Madrigal.
  • Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Evercore ISI, Piper Sandler, UBS Investment Bank and Citizens JMP are acting as joint bookrunning managers of the proposed offering.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million

Retrieved on: 
Tuesday, March 12, 2024
BofA Securities, Montgomery Street, Exercise, Madison Avenue, Atopic dermatitis, Goldman Sachs, Telephone, SAN, Chronic obstructive pulmonary disease, Sale, Attention, Security (finance), Lexington Avenue, Asthma, Suite, Apsis, Prospectus, Therapy, Jefferies, Jefferies Group

The aggregate gross proceeds to Apogee from the offering were approximately $483.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.

Key Points: 
  • The aggregate gross proceeds to Apogee from the offering were approximately $483.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.
  • All of the shares were offered by Apogee.
  • Jefferies, BofA Securities, Goldman Sachs & Co. LLC, TD Cowen and Stifel acted as joint book-running managers for the offering.
  • Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on March 7, 2024.